In order to guarantee cancer treatment, as well as safe and timely specialized care, the National Institute of Neoplastic Diseases (INEN)
will process molecular tests in about 40 minutes to diagnose COVID-19 in its patients.
In this regard, INEN Institutional Chief Eduardo Payet highlighted the work carried out by the Microbiology Laboratory team of professionals dedicated to the implementation of this specialized area for the benefit of cancer patients, who belong to the risk group because of their weak immune system.
Moreover, he stressed the importance of this technology, which will allow them to process up to 80 tests per day and obtain results in the short term, generating a positive impact on the management of healthcare procedures.
Minimum human contact
According to INS institutional Chief Cesar Cabezas, this authorization is the result of INEN health team's joint efforts and the technical support of INS, which contributes to the fight against COVID-19 in the country.
It should be noted that this diagnosis method is not only safe for patients, but also for specialists, due to the minimal human contact during the procedure, and is aligned with the biosafety protocols recommended by the World Health Organization (WHO)
During an event held on Tuesday, the INS head delivered the Certificate of Compliance with the Requirements to Perform Molecular Diagnostic Testing for SARS-CoV-2 to the head of INEN.
By doing so, INEN has taken a major step forward in terms of implementation of cutting-edge technology for the care of its patients.